Detalles de la búsqueda
1.
Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer.
J Clin Oncol
; 23(11): 2544-55, 2005 Apr 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-15753462
Resultados
1 -
1
de 1
1
Próxima >
>>